Skip to main content
Delfa

← All assets

ABT-126

7 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

7

Ongoing

0

Recruiting

0

Completed

5

Sites

177

Countries

13

Endpoints

44

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 44 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
2
Phase 2
5

Trials by status

Completed
5
Terminated
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
12
Safety / tolerability / PK
10
Other (unclassified)
7
Global cognition
5
Caregiver / quality of life
4
Memory
2
Function / daily living
2
Other clinical outcomes
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 8 of 44 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADCS-Activities of Daily Living (ADCS-ADL)Function

2

Mini-Mental State Examination (MMSE)Cognition

2

Neuropsychiatric Inventory (NPI)Behavior

2

ADAS-CogCognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

7 of 7

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT01549834Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

ABT-126

Alzheimer’s disease

mild-to-moderate ADPh 2Completed43Oct 20131
NCT01690195Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

ABT-126

Alzheimer’s disease

mild-to-moderate ADPh 2Terminated39Feb 20141
NCT01527916Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

ABT-126, Donepezil

Alzheimer’s disease

mild-to-moderate ADPh 2Completed33Nov 20131
NCT00948909Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

ABT-126, Donepezil

Alzheimer’s disease

Alzheimer's diseasePh 2Completed29Nov 20101
NCT01676935This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

ABT-126

Alzheimer’s disease

mild-to-moderate ADPh 2Terminated29Mar 20141
NCT01482845A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

ABT-126

Alzheimer’s disease

Alzheimer's diseasePh 1Completed3Mar 2012-
NCT00867399A Safety and Tolerability Study of ABT-126 in Elderly

ABT-126

Alzheimer’s disease

MMSE 27Ph 1Completed1May 2009-

Showing 1-7 of 7 trials